News

The efficacy of Welchol compared to placebo was evaluated in patients receiving metformin-based or sulfonylurea-based therapy (either monotherapy or in combination with other antidiabetes therapy) in two separate

Study 211 is a Phase II, open-label, single-arm study evaluating the efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer who had

In this interim analysis, 25 of 46 enrolled patients had sufficient data available for evaluation. The median follow up of the patients was six months (range two to

The Opus study is a randomized first-line Phase II study of 337 patients comparing Erbitux plus Folfox to Folfox alone in epidermal growth factor receptor (EGFR)-expressing colorectal cancer

Under the terms of the agreement, Dyax has been granted a non-exclusive research and development license for use of Novozymes’ technology to develop albumin fusions of Kunitz domain

Early results on the first three patients from this investigator-initiated study showed the increase in breast volume was maintained at three months and that the tissue remained soft

Top-line data from this Phase II safety and efficacy study of intestinal trefoil factor (rhITF) administered to colorectal cancer patients at high risk of developing oral mucositis (OM)

Overall, custirsen was well-tolerated in combination with either docetaxel or mitoxantrone administered as second-line chemotherapy in patients with hormone refractory prostate cancer. Custirsen was associated with durable pain

The Phase IIa study met its primary endpoint by showing a statistically significant reduction in mean 24-hour systolic ambulatory blood pressure over placebo. The study also showed statistically